Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Monotherapy or With Axitinib in Advanced/Metastatic RCC
NCT05256472Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in renal cell carcinoma (RCC), sponsored by Akeso, Inc.. Started Jul 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05256472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256472.